<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155479</url>
  </required_header>
  <id_info>
    <org_study_id>P05664</org_study_id>
    <secondary_id>2009-013552-72</secondary_id>
    <secondary_id>MK-3814-024</secondary_id>
    <nct_id>NCT01155479</nct_id>
  </id_info>
  <brief_title>A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)</brief_title>
  <acronym>PARADYSE</acronym>
  <official_title>A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a one year, 2-part study to determine the efficacy and safety of preladenant, an
      adenosine type 2a (A2a) receptor antagonist. The purpose of Part 1 (first 26 weeks) is to
      determine if preladenant is effective in the treatment of early Parkinson's Disease. The
      purpose of Part 2 (second 26 weeks) is to determine if preladenant is safe and well
      tolerated. The primary efficacy hypothesis is that at least the 10 mg twice daily dose of
      preladenant is superior to placebo as measured by the change from Baseline to Week 26 in the
      sum of Unified Parkinson's Disease Rating Scale (UPDRS) Parts 2 and 3 scores (UPDRS2+3).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termininated for business reasons
  </why_stopped>
  <start_date type="Actual">July 6, 2010</start_date>
  <completion_date type="Actual">July 16, 2013</completion_date>
  <primary_completion_date type="Actual">July 16, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The UPDRS Part 3 is the Motor Examination (Total Motor Score [TMS]) and is defined as the total score, ranging from 0-108 as determined by the physician, of the tests given in the motor examination section. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. Change from baseline was analyzed using a constrained longitudinal analysis (cLDA) model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) in Part 1</measure>
    <time_frame>Day 1 to Week 26</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Due to an AE in Part 1</measure>
    <time_frame>Day 1 to Week 26</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) in Part 2</measure>
    <time_frame>Week 27 to Week 52</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Due to an AE in Part 2</measure>
    <time_frame>Week 27 to Week 52</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders (Participants With a â‰¥20% Improvement in UPDRS2+3)</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>UPDRS is a clinician based rating scale used to measure motor impairments and disability; it assesses 6 features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. UPDRS Part 2 is Activities of Daily Living score and ranges from 0-52. UPDRS Part 3 is Motor Examination and ranges from 0-108. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. A Responder is defined as a participant with at least 20% improvement in UPDRS2+3 from Baseline to Week 26 (End of Part 1 Treatment); a participant with at least a 20% decrease from Baseline score in UPDRS2+3 is defined as a responder. The proportion of Responders was analyzed using a generalized linear mixed model with treatment effect, strata and Baseline UPDRS2+3 as a covariate, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the UPDRS Part 2 Score (Activities of Daily Living [ADL])</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician with the higher score indicating the worse condition. Change from baseline was analyzed using a cLDA model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1022</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant 2 mg tablet</intervention_name>
    <description>Preladenant 2 mg oral tablet taken twice daily</description>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant 5 mg tablet</intervention_name>
    <description>Preladenant 5 mg oral tablet taken twice daily</description>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant 10 mg tablet</intervention_name>
    <description>Preladenant 10 mg oral tablet taken twice daily</description>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline 1 mg capsule</intervention_name>
    <description>Rasagiline 1 mg oral capsule taken once daily</description>
    <arm_group_label>Rasagiline</arm_group_label>
    <other_name>Azilect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Rasagiline 1 mg capsule</intervention_name>
    <description>Placebo for rasagiline 1 mg oral capsule taken once daily</description>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Preladenant</intervention_name>
    <description>Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rasagiline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of idiopathic PD for &lt; 5 years.

          -  If receiving amantadine and/or anticholinergics, must have been on a stable regimen of
             treatment for at least the 5 weeks immediately before Screening. (Note: Participants
             who are not taking any medications for PD are permitted to enroll in this trial.)

          -  Must have a UPDRS Part 3 score of â‰¥10, a Hoehn and Yahr Stage â‰¤3, be â‰¥30 to â‰¤85 years
             of age, and have results of Screening clinical laboratory tests drawn within 5 weeks
             prior to randomization, clinically acceptable to the investigator, and not within the
             parameters specified for exclusion.

          -  If sexually active or plan to be sexually active, must agree to use a highly effective
             method of birth control while the participant is in the study and for 2 weeks after
             the last dose of study drug. A male participant must also not donate sperm during the
             trial and within 2 weeks after the last dose of study drug.

        Exclusion Criteria:

          -  Must not have a form of drug-induced or atypical Parkinsonism, cognitive impairment
             (ie, Montreal Cognitive Assessment [MoCA] score &lt;22), bipolar disorder, untreated
             major depressive disorder, schizophrenia, or other psychotic disorder; history of
             exposure to a known neurotoxin, or any neurological features not consistent with the
             diagnosis of PD as assessed by the investigator.

          -  Must not have had surgery for PD.

          -  Must not have a history of repeated strokes with stepwise progression of Parkinsonism
             or head injuries, or a stroke within 6 months of screening; poorly controlled
             diabetes; abnormal renal function; or a severe or ongoing unstable medical condition.

          -  Must not have failed to show a therapeutic response if a diagnostic levodopa (L dopa)
             challenge had been done with a large test dose (&gt;500 mg) of L dopa (if malabsorption
             excluded), or failed to respond to an adequate previous treatment with dopaminergic
             therapy.

          -  Must not have been treated with L dopa or dopamine agonists for 30 days or more. A
             participant who has been treated with L-dopa or dopamine agonists for &lt;30 days will be
             allowed to enter the study. These participants must stop taking dopaminergic
             medication 30 days prior to Randomization.

          -  Must not be at imminent risk of self-harm or harm to others.

          -  Must not have elevated blood pressure (BP) (systolic BP â‰¥150 mm Hg or diastolic BP â‰¥95
             mm Hg) that cannot be adequately controlled with antihypertensive medication, as
             demonstrated by 2 BP measurements meeting acceptable BP criterion at consecutive
             scheduled or unscheduled visits between Screening and Randomization (a 5-6 week
             period), one of which must be the Randomization visit.

          -  Must not have had any clinically significant cardiovascular event or procedure for 6
             months prior to Randomization, including, but not limited to, myocardial infarction,
             angioplasty, unstable angina, or heart failure; and a participant must not have heart
             failure staged New York Heart Association Class III or IV.

          -  Must not have an alanine aminotransferase (ALT) or aspartate amino transferase (AST) â‰¥
             3 x the upper limit of normal (ULN) or total bilirubin (T BIL) â‰¥ 1.5 x ULN.

          -  Must not have active serologically-confirmed hepatic dysfunction (defined as viral
             infection [Hepatitis B, C, or E; Epstein-Barr virus (EBV)]; cytomegalovirus [CMV] or a
             history of diagnosis of drug- or alcohol-induced hepatic toxicity or frank hepatitis,
             or a history of diagnosis of drug- or alcohol-induced hepatic toxicity or frank
             hepatitis.)

          -  Must not have a history within the past 5 years of a primary or recurrent malignant
             disease with the exception of adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or in situ prostate cancer with a normal
             prostate-specific antigen (PSA) post resection.

          -  Must not have received certain prespecified medications or ingested high
             tyramine-containing aged cheeses (eg, Stilton) for a prespecified time window before
             the trial, during the trial, and for 2 weeks after the trial.

          -  Must not have an average daily consumption of more than three 4 ounce glasses (118 mL)
             of wine or the equivalent.

          -  Must not have a severe or ongoing unstable medical condition (eg, any form of
             clinically significant cardiac disease, symptomatic orthostatic hypotension, seizures,
             or alcohol/drug dependence.)

          -  Must not have allergy/sensitivity to investigational product(s) or its/their
             excipients.

          -  Must not be breast-feeding, considering breast-feeding, pregnant or intending to
             become pregnant.

          -  Must not have used preladenant ever, or any investigational drugs within 90 days
             immediately before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.</citation>
    <PMID>28490648</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <results_first_submitted>June 15, 2016</results_first_submitted>
  <results_first_submitted_qc>June 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2016</results_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P05664&amp;kw=P05664&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with a diagnosis of idiopathic PD for less than 5 years were selected to participate in this study.</recruitment_details>
      <pre_assignment_details>In Part 1, participants were randomized to one of five treatment groups and treated for 26 weeks. In Part 2, which was conducted for an additional 26 weeks, participants continued taking the same study treatment from Part 1, except for placebo participants who were re-assigned to receive preladenant 5 mg twice daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Preladenant 2 mg</title>
          <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="P2">
          <title>Preladenant 5 mg</title>
          <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="P3">
          <title>Preladenant 10 mg</title>
          <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).</description>
        </group>
        <group group_id="P5">
          <title>Rasagiline</title>
          <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="204"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="204"/>
                <participants group_id="P5" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="198"/>
                <participants group_id="P5" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="177"/>
                <participants group_id="P5" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Protocol Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="177"/>
                <participants group_id="P5" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="127"/>
                <participants group_id="P5" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Participants as Randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Preladenant 2 mg</title>
          <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="B2">
          <title>Preladenant 5 mg</title>
          <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="B3">
          <title>Preladenant 10 mg</title>
          <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).</description>
        </group>
        <group group_id="B5">
          <title>Rasagiline</title>
          <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="204"/>
            <count group_id="B3" value="206"/>
            <count group_id="B4" value="204"/>
            <count group_id="B5" value="204"/>
            <count group_id="B6" value="1022"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="10.5"/>
                    <measurement group_id="B2" value="62.3" spread="10.2"/>
                    <measurement group_id="B3" value="63.8" spread="11.1"/>
                    <measurement group_id="B4" value="63.3" spread="10.0"/>
                    <measurement group_id="B5" value="62.9" spread="10.2"/>
                    <measurement group_id="B6" value="63.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="85"/>
                    <measurement group_id="B6" value="425"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="119"/>
                    <measurement group_id="B6" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Sum of Unified Parkinsonâ€™s Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)</title>
        <description>The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The UPDRS Part 3 is the Motor Examination (Total Motor Score [TMS]) and is defined as the total score, ranging from 0-108 as determined by the physician, of the tests given in the motor examination section. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. Change from baseline was analyzed using a constrained longitudinal analysis (cLDA) model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set (FAS): All randomized and treated participants with at least one post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 1)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 1)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 1)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 1)</title>
            <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 1)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Sum of Unified Parkinsonâ€™s Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)</title>
          <description>The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The UPDRS Part 3 is the Motor Examination (Total Motor Score [TMS]) and is defined as the total score, ranging from 0-108 as determined by the physician, of the tests given in the motor examination section. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. Change from baseline was analyzed using a constrained longitudinal analysis (cLDA) model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect.</description>
          <population>Full Analysis Set (FAS): All randomized and treated participants with at least one post-baseline value.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="195"/>
                <count group_id="O5" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.63"/>
                    <measurement group_id="O2" value="-1.0" spread="0.60"/>
                    <measurement group_id="O3" value="-1.8" spread="0.61"/>
                    <measurement group_id="O4" value="-2.2" spread="0.61"/>
                    <measurement group_id="O5" value="-1.9" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 2 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>4.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 5 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1382</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 10 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6378</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rasagiline (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6923</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders (Participants With a â‰¥20% Improvement in UPDRS2+3)</title>
        <description>UPDRS is a clinician based rating scale used to measure motor impairments and disability; it assesses 6 features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. UPDRS Part 2 is Activities of Daily Living score and ranges from 0-52. UPDRS Part 3 is Motor Examination and ranges from 0-108. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. A Responder is defined as a participant with at least 20% improvement in UPDRS2+3 from Baseline to Week 26 (End of Part 1 Treatment); a participant with at least a 20% decrease from Baseline score in UPDRS2+3 is defined as a responder. The proportion of Responders was analyzed using a generalized linear mixed model with treatment effect, strata and Baseline UPDRS2+3 as a covariate, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set (FAS): All randomized and treated participants with at least one post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 1)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks. The number of participants analyzed (195) represents the number of randomized and treated participants with at least one post-treatment value.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 1)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks. The number of participants analyzed (202) represents the number of randomized and treated participants with at least one post-treatment value.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 1)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks. The number of participants analyzed (200) represents the number of randomized and treated participants with at least one post-treatment value.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 1)</title>
            <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks. The number of participants analyzed (195) represents the number of randomized and treated participants with at least one post-treatment value.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 1)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks. The number of participants analyzed (195) represents the number of randomized and treated participants with at least one post-treatment value.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders (Participants With a â‰¥20% Improvement in UPDRS2+3)</title>
          <description>UPDRS is a clinician based rating scale used to measure motor impairments and disability; it assesses 6 features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. UPDRS Part 2 is Activities of Daily Living score and ranges from 0-52. UPDRS Part 3 is Motor Examination and ranges from 0-108. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. A Responder is defined as a participant with at least 20% improvement in UPDRS2+3 from Baseline to Week 26 (End of Part 1 Treatment); a participant with at least a 20% decrease from Baseline score in UPDRS2+3 is defined as a responder. The proportion of Responders was analyzed using a generalized linear mixed model with treatment effect, strata and Baseline UPDRS2+3 as a covariate, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
          <population>Full Analysis Set (FAS): All randomized and treated participants with at least one post-baseline value.</population>
          <units>Percentage of Responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="195"/>
                <count group_id="O5" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.90" lower_limit="18.95" upper_limit="34.33"/>
                    <measurement group_id="O2" value="29.50" lower_limit="22.50" upper_limit="37.72"/>
                    <measurement group_id="O3" value="31.50" lower_limit="24.06" upper_limit="40.02"/>
                    <measurement group_id="O4" value="35.20" lower_limit="27.49" upper_limit="43.82"/>
                    <measurement group_id="O5" value="33.10" lower_limit="25.60" upper_limit="41.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 2 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0785</p_value>
            <p_value_desc>p-value is for the estimated Odds Ratio based on a generalized linear mixed model with baseline UPDRS2+3 as a covariate and treatment-by-time interaction as fixed effect and participant as random effect.</p_value_desc>
            <method>generalized linear mixed model</method>
            <param_type>Difference vs Placebo (%)</param_type>
            <param_value>-9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.0</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 5 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2735</p_value>
            <p_value_desc>p-value is for the estimated Odds Ratio based on a generalized linear mixed model with baseline UPDRS2+3 as a covariate and treatment-by-time interaction as fixed effect and participant as random effect.</p_value_desc>
            <method>generalized linear mixed model</method>
            <param_type>Difference vs Placebo (%)</param_type>
            <param_value>-6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.6</ci_lower_limit>
            <ci_upper_limit>5.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 10 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4823</p_value>
            <p_value_desc>p-value is for the estimated Odds Ratio based on a generalized linear mixed model with baseline UPDRS2+3 as a covariate and treatment-by-time interaction as fixed effect and participant as random effect.</p_value_desc>
            <method>generalized linear mixed model</method>
            <param_type>Difference vs Placebo (%)</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>7.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rasagiline (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6827</p_value>
            <p_value_desc>p-value is for the estimated Odds Ratio based on a generalized linear mixed model with baseline UPDRS2+3 as a covariate and treatment-by-time interaction as fixed effect and participant as random effect.</p_value_desc>
            <method>generalized linear mixed model</method>
            <param_type>Difference vs Placebo (%)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>9.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the UPDRS Part 2 Score (Activities of Daily Living [ADL])</title>
        <description>The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician with the higher score indicating the worse condition. Change from baseline was analyzed using a cLDA model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set (FAS): All randomized and treated participants with at least one post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 1)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 1)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 1)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 1)</title>
            <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 1)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the UPDRS Part 2 Score (Activities of Daily Living [ADL])</title>
          <description>The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician with the higher score indicating the worse condition. Change from baseline was analyzed using a cLDA model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect.</description>
          <population>Full Analysis Set (FAS): All randomized and treated participants with at least one post-baseline value.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="195"/>
                <count group_id="O5" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.22"/>
                    <measurement group_id="O2" value="0.10" spread="0.21"/>
                    <measurement group_id="O3" value="-0.20" spread="0.21"/>
                    <measurement group_id="O4" value="-0.40" spread="0.21"/>
                    <measurement group_id="O5" value="-0.20" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 2 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0235</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 5 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1093</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Preladenant 10 mg (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5756</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rasagiline (Part 1) vs Placebo (Part 1)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6657</p_value>
            <method>constrained longitudinal analysis</method>
            <param_type>Difference in Estimated Means</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) in Part 1</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
        <time_frame>Day 1 to Week 26</time_frame>
        <population>All Participants as Treated: All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 1)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 1)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 1)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 1)</title>
            <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 1)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) in Part 1</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
          <population>All Participants as Treated: All participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="198"/>
                <count group_id="O5" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="102"/>
                    <measurement group_id="O5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Due to an AE in Part 1</title>
        <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
        <time_frame>Day 1 to Week 26</time_frame>
        <population>All Participants as Treated: All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 1)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 1)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 1)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 1)</title>
            <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 1)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Due to an AE in Part 1</title>
          <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
          <population>All Participants as Treated: All participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="198"/>
                <count group_id="O5" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) in Part 2</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
        <time_frame>Week 27 to Week 52</time_frame>
        <population>All Participants as Treated: All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 2)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 2)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 2)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 2)</title>
            <description>Participants who had received placebo to preladenant in Part 1 received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 2)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) in Part 2</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
          <population>All Participants as Treated: All participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="177"/>
                <count group_id="O5" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="120"/>
                    <measurement group_id="O5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Due to an AE in Part 2</title>
        <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
        <time_frame>Week 27 to Week 52</time_frame>
        <population>All Participants as Treated (APaT): All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg (Part 2)</title>
            <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg (Part 2)</title>
            <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg (Part 2)</title>
            <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Part 2)</title>
            <description>Participants who had received placebo to preladenant in Part 1 received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline (Part 2)</title>
            <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Due to an AE in Part 2</title>
          <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</description>
          <population>All Participants as Treated (APaT): All participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="177"/>
                <count group_id="O5" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 weeks (including 2 weeks of follow-up)</time_frame>
      <desc>All Participants as Treated (APaT) - includes all participants who received at least one (1) dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Preladenant 2 mg - Part 1</title>
          <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks (Part 1).</description>
        </group>
        <group group_id="E2">
          <title>Preladenant 5 mg - Part 1</title>
          <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks (Part 1).</description>
        </group>
        <group group_id="E3">
          <title>Preladenant 10 mg - Part 1</title>
          <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks (Part 1).</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Part 1</title>
          <description>Participants received placebo for preladenant and placebo for rasagiline in the AM followed by placebo for preladenant in the PM for 26 weeks (Part 1).</description>
        </group>
        <group group_id="E5">
          <title>Rasagiline - Part 1</title>
          <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks (Part 1).</description>
        </group>
        <group group_id="E6">
          <title>Preladenant 2 mg - Part 2</title>
          <description>Participants received preladenant 2 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 2 mg oral tablet in PM for 26 weeks (Part 2).</description>
        </group>
        <group group_id="E7">
          <title>Preladenant 5 mg - Part 2</title>
          <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg in the PM for 26 weeks (Part 2).</description>
        </group>
        <group group_id="E8">
          <title>Preladenant 10 mg - Part 2</title>
          <description>Participants received preladenant 10 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 10 mg in the PM for 26 weeks (Part 2).</description>
        </group>
        <group group_id="E9">
          <title>Placebo/Preladenant 5 Mg-Part 2</title>
          <description>Participants received preladenant 5 mg oral tablet and placebo for rasagiline in the AM followed by preladenant 5 mg oral tablet in the PM for 26 weeks (Part 2).</description>
        </group>
        <group group_id="E10">
          <title>Rasagiline - Part 2</title>
          <description>Participants received rasagiline 1 mg oral capsule and placebo for preladenant in the AM followed by placebo for preladenant in PM for 26 weeks (Part 2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Antinuclear Antibody Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vitamin B12 Deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Osteoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinonasal Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression Suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pregnancy of Partner</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="198"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="166"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="177"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="177"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E9" events="8" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E10" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="203"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E10" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="203"/>
                <counts group_id="E6" events="16" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E8" events="11" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E10" events="8" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E9" events="10" subjects_affected="8" subjects_at_risk="177"/>
                <counts group_id="E10" events="7" subjects_affected="6" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The Investigator further agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

